Status:
WITHDRAWN
Calcimimetics in Hypophosphatemic Rickets
Lead Sponsor:
Children's Mercy Hospital Kansas City
Conditions:
Familial Hypophosphatemic Rickets
Eligibility:
All Genders
5-21 years
Phase:
NA
Brief Summary
Currently, large oral doses of phosphate and 1,25(OH)2D (calcitriol) are the standard treatment of patients with familial hypophosphatemic rickets (XLH). While this therapy is effective in healing the...
Eligibility Criteria
Inclusion
- Patients with XLH
- Age 5-21 years old
- From the Renal and Endocrinology Clinics who have been in a stable clinical, biochemical and radiological condition for the preceding 9 months
- Who have not received Cinacalcet before
Exclusion
- Treatment with growth hormone
- Inability to swallow pills.
- An orthopedic surgery or braces in the past 9 months, or scheduled within 9 months of start.
- Pregnancy
- History of seizure disorder
- Abnormal liver functions (which may change the drug's AUC)
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00844740
Start Date
March 1 2009
End Date
March 1 2012
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108